IP Library Granted Patent US 10,065,999
Granted Patent B2
US 10,065,999 · App. 14/576,706 · Granted Sep 4, 2018

Methods for protecting dopaminergic neurons from stress and promoting proliferation and differentiation of oligodendrocyte progenitors by NRG-2

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,065,999
App. No.
14/576,706
Granted
Sep 4, 2018
Kind
B2
Abstract

The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.

Claims (9)

1. A method for increasing the mitogenesis, survival, growth, or differentiation of neuronal-associated cells chosen from oligodendrocyte progenitor cells and olfactory bulb ensheathing cells, said method comprising contacting a human neuregulin 2 (NRG-2) polypeptide comprising the amino acid sequence of SEQ ID NO: 4 to said cells in an amount effective for increasing the mitogenesis, survival, growth, or differentiation of said cells.

2. A method of stimulating mitogenesis of neuronal associated cells chosen from oligodendrocyte progenitor cells and olfactory bulb ensheathing cells, said method comprising contacting said cells with a human neuregulin 2 (NRG-2) polypeptide comprising the amino acid sequence of SEQ ID NO: 4.

3. A method of affecting cellular communication between a neuronal-associated cell and a neuronal cell in a mammal, wherein the neuronal-associated cell is chosen from oligodendrocyte progenitor cells and olfactory bulb ensheathing cells, the method comprising:

administering a human neuregulin 2 (NRG-2) NRG-2 polypeptide comprising the amino acid sequence domain of SEQ ID NO: 4 to said mammal wherein said NRG-2 polypeptide interacts with said neuronal-associated cell,

resulting in the production of at least one neurotrophic agent by said neuronal-associated cell, and

increasing mitogenesis, survival, growth, differentiation, or neurite outgrowth of said neuronal cell and/or said neuronal-associated cell.

4. The method of claim 3 , wherein said mammal is a human.

5. The method of claim 3 , wherein said affecting cellular communication is in the central nervous system of a mammal.

6. The method of claim 3 , wherein said affecting cellular communication is in the peripheral nervous system of a mammal.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NEURONEX, INC.; CIVITAS THERAPEUTICS, INC.; ACORDA THERAPEUTICS, INC.
Reel/Frame 042643/0878 →
SECURITY INTEREST Recorded Jun 10, 2016
From: ACORDA THERAPEUTICS, INC.; CIVITAS THERAPEUTICS, INC.; NEURONEX, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 038950/0436 →